Online inquiry

IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6620MR)

This product GTTS-WQ6620MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6620MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7848MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ4414MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ1130MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ11072MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ939MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ10764MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ5303MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ530MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 4D11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW